A Retrospective Study on Clinical Characteristics and Outcomes of Patients With Pneumonia
- Sponsor
- Zhonghao Fang
- Study ID
- NCT07574866
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Pneumonia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.
Key Dates
- First listed
- May 8, 2026
- Start date
- Apr 30, 2026
- Status verified
- Apr 2026
- Primary completion
- Oct 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Arms
- Arm: pneumoniapneumonia
Primary Outcome Measure
28-day all-cause mortality rate [ Time Frame: 28 days after admission ]
Central Contacts
- Liang Peng, Doctor86-020-85959142
Related Studies
- Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Study of Lung Proteins in Patients With PneumoniaRecruiting · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
- The Role of Circadian Clock Proteins in Innate and Adaptive ImmunityRecruiting · Washington University School of Medicine · St Louis, Missouri
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Recruiting · Duke University · Little Rock, Arkansas